Nov 20 (Reuters) – The US Food and Drug Administration declined to approve Capricor Therapeutics’ experimental cell therapy for a fatal inherited disease that weakens muscle, the health regulator said on Friday, adding to a string of regulatory setbacks for the biotech firm.
Shares of the company were down 72% in extended trading.
Capricor was seeking approval for the therapy, known as deramiocel, to preserve upper-limb function in Duchenne muscular dystrophy patients.
The agency said serious data integrity problems in a key clinical trial meant the evidence did not meet the standard for approval.
Duchenne is a fatal genetic disease that primarily affects boys and causes progressive muscle weakness, loss of mobility, heart complications and premature death.
The regulatory rejection deals a heavy blow to Capricor, threatening its lead experimental asset and clouding the company’s commercial prospects after months of efforts to salvage the application by narrowing its focus to arm and hand movement.
The decision follows a nine-to-three vote in July in which the FDA’s advisers said the evidence presented at the time did not establish deramiocel’s effectiveness in Duchenne-related heart disease. Capricor subsequently amended its application with new data supporting a refined proposed indication focused on upper limb function.
(Reporting by Kunal Das, Sahil Pandey and Kamal Choudhury in Bengaluru. Editing by Alan Barona and Perla Velasco)

